Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer

被引:0
作者
Joanna Achinger-Kawecka
Fatima Valdes-Mora
Phuc-Loi Luu
Katherine A. Giles
C. Elizabeth Caldon
Wenjia Qu
Shalima Nair
Sebastian Soto
Warwick J. Locke
Nicole S. Yeo-Teh
Cathryn M. Gould
Qian Du
Grady C. Smith
Irene R. Ramos
Kristine F. Fernandez
Dave S. Hoon
Julia M. W. Gee
Clare Stirzaker
Susan J. Clark
机构
[1] Garvan Institute of Medical Research,Epigenetics Research Laboratory, Genomics and Epigenetics Theme
[2] UNSW Sydney,St. Vincent’s Clinical School, Faculty of Medicine
[3] The Kinghorn Cancer Centre,Cancer Theme
[4] John Wayne Cancer Institute,Department of Translational Molecular Medicine
[5] Cardiff University,Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences
来源
Nature Communications | / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, but the underlying molecular mechanisms are largely unknown. Here, we show that 3-dimensional (3D) chromatin interactions both within and between topologically associating domains (TADs) frequently change in ER+ endocrine-resistant breast cancer cells and that the differential interactions are enriched for resistance-associated genetic variants at CTCF-bound anchors. Ectopic chromatin interactions are preferentially enriched at active enhancers and promoters and ER binding sites, and are associated with altered expression of ER-regulated genes, consistent with dynamic remodelling of ER pathways accompanying the development of endocrine resistance. We observe that loss of 3D chromatin interactions often occurs coincidently with hypermethylation and loss of ER binding. Alterations in active A and inactive B chromosomal compartments are also associated with decreased ER binding and atypical interactions and gene expression. Together, our results suggest that 3D epigenome remodelling is a key mechanism underlying endocrine resistance in ER+ breast cancer.
引用
收藏
相关论文
共 50 条
[41]   CHARACTERIZATION OF CATECHOLESTROGEN MEMBRANE-BINDING SITES IN ESTROGEN-RECEPTOR POSITIVE AND NEGATIVE HUMAN-BREAST CANCER CELL-LINES [J].
VANDEWALLE, B ;
HORNEZ, L ;
LEFEBVRE, J .
JOURNAL OF RECEPTOR RESEARCH, 1988, 8 (05) :699-712
[42]   Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: An Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators against Endocrine-Resistant Breast Cancer [J].
Deng, Xiangping ;
Xie, Baohua ;
Li, Qiuzi ;
Xiao, Yuan ;
Hu, Zhiye ;
Deng, Xiaofei ;
Fang, Pingping ;
Dong, Chune ;
Zhou, Hai-Bing ;
Huang, Jian .
JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (11) :7993-8010
[43]   TYPE-II ESTROGEN BINDING-SITES AND GROWTH INHIBITORY EFFECT OF BIOFLAVONOIDS AND TAMOXIFEN ON A MULTIDRUG-RESISTANT ESTROGEN-RECEPTOR NEGATIVE HUMAN BREAST-CANCER CELL-LINE [J].
SCAMBIA, G ;
RANELLETTI, FO ;
PANICI, PB ;
PIANTELLI, M ;
BONANNO, G ;
DEVINCENZO, R ;
FERRANDINA, G ;
MANCUSO, S .
BREAST CANCER RESEARCH AND TREATMENT, 1992, 22 (02) :164-164
[44]   Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance [J].
Zhou, Yufan ;
Gerrard, Diana L. ;
Wang, Junbai ;
Li, Tian ;
Yang, Yini ;
Fritz, Andrew J. ;
Rajendran, Mahitha ;
Fu, Xiaoyong ;
Schiff, Rachel ;
Lin, Shili ;
Frietze, Seth ;
Jin, Victor X. .
NATURE COMMUNICATIONS, 2019, 10 (1)
[45]   Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance [J].
Yufan Zhou ;
Diana L. Gerrard ;
Junbai Wang ;
Tian Li ;
Yini Yang ;
Andrew J. Fritz ;
Mahitha Rajendran ;
Xiaoyong Fu ;
Gary Stein ;
Rachel Schiff ;
Shili Lin ;
Seth Frietze ;
Victor X. Jin .
Nature Communications, 10
[46]   Potent estrogen receptor β agonists with inhibitory activity in vitro, fail to suppress xenografts of endocrine-resistant cyclin-dependent kinase 4/6 inhibitor-resistant breast cancer cells [J].
Marcho, Lynn M. ;
Coss, Christopher C. ;
Xu, Menglin ;
Datta, Jharna ;
Manouchehri, Jasmine M. ;
Cherian, Mathew A. .
FRONTIERS IN ONCOLOGY, 2025, 15
[47]   The role of ca2 in regulating 3d chromatin structure in tamoxifen resistant breast cancer [J].
Choppavarapu, Lavanya ;
Fang, Kun ;
Liu, Tianxiang ;
Ohihoin, Aigbe G. ;
Jin, Victor X. .
CANCER RESEARCH, 2025, 85 (08)
[48]   IMMUNOCYTOCHEMICAL DETERMINATION OF ESTROGEN-RECEPTOR, PROGESTERONE-RECEPTOR, AND 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR IN BREAST-CANCER AND RELATIONSHIP TO PROGNOSIS [J].
BERGER, U ;
MCCLELLAND, RA ;
WILSON, P ;
GREENE, GL ;
HAUSSLER, MR ;
PIKE, JW ;
COLSTON, K ;
EASTON, D ;
COOMBES, RC .
CANCER RESEARCH, 1991, 51 (01) :239-244
[49]   Discovery of GDC-0810 a novel, non-steroidal selective estrogen receptor degrader with robust activity in pre-clinical models of endocrine-resistant breast cancer [J].
Joseph, James ;
Govek, Steven ;
Darimont, Beatrice ;
Brigham, Daniel ;
Aparicio, Anna ;
Bischoff, Eric ;
Kahraman, Mehmet ;
Nannini, Michelle ;
Kaufman, Joshua ;
Lai, Andily ;
Lee, Kyoung-Jin ;
Oeh, Jason ;
Lu, Nhin ;
Zhou, Wei ;
Moon, Michael ;
Qian, Jing ;
Sensintaffar, John ;
Shao, Gang ;
Sampath, Deepak ;
Friedman, Lori S. ;
Rix, Peter ;
Heyman, Richard A. ;
Smith, Nicholas ;
Hager, Jeffrey H. .
CANCER RESEARCH, 2015, 75
[50]   "Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer" (vol 253, 115328, 2023) [J].
Xin, Lilan ;
Min, Jian ;
Hu, Hebing ;
Li, Yuanyuan ;
Du, Chuanqian ;
Xie, Baohua ;
Cheng, Yan ;
Deng, Xiaofei ;
Deng, Xiangping ;
Shen, Kang ;
Huang, Jian ;
Chen, Chun-Chi ;
Guo, Rey-Ting ;
Dong, Chune ;
Zhou, Hai-Bing .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 276